To the Editor The role of tumor mutation burden (TMB) in predicting cancer immunotherapy response is predicated on the well-supported hypothesis that the immune system is able to recognize and respond to cancer-specific neoantigens. Even as a bulk and indirect neoantigen surrogate, TMB has been increasingly accepted as a biomarker of response. In their recent Viewpoint, Addeo et al1 compellingly described the adoption of TMB as overzealous “groupthink,” with real-world implications for patients. The implications are broad, with TMB influencing internationally recommended treatment guidelines, US Food and Drug Administration approval, and clinical practice. We also note an expanding cohort of clinical trials (eg, NCT03668119, NCT03178552, NCT03519412) that are actively using TMB status as an inclusion criterion.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Wood MA, Nellore A, Thompson RF. Tumor Mutation Burden—From Doubts to Concerns. JAMA Oncol. Published online October 24, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.4138
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: